ARA-290 (cibinetide) improved neuropathic pain and regrew nerve fibres

In people with sarcoidosis and small-fibre nerve damage, 28 days of treatment beat placebo.

ARA-290 is a small peptide designed to activate the so-called innate repair receptor, which dampens inflammatory processes and stimulates tissue repair. It was tested in people with sarcoidosis and documented small nerve fibre loss.

In this blinded, placebo-controlled trial, 28 days of daily dosing improved neuropathic symptoms and increased corneal nerve fibre density, an objective measure of regeneration that did not change with placebo.

In three points

Placebo-controlled human trial
Fewer neuropathic symptoms in 28 days
More corneal nerve fibres, measured objectively

Compounds mentioned

ARA-290 cibinetide

Original source: ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density
PubMed · Molecular Medicine

Plain-language summary by SYNTRA LABS based on the original publication and checked against its source. It is not medical advice or a recommendation for use. SYNTRA LABS compounds are for research use only and not for human consumption.